The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective ...

The panel, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see ...

UniQure had planned to seek accelerated approval for AMT-130 early 2026, but then said its plans were stalled after ...

The company, founded by UC Berkeley scientists including Jennifer Doudna, is preparing to test its lead candidate STX-1150 in ...

The company received FDA clearance to launch a Phase I trial of its therapy, which it says can overcome safety and efficacy concerns related to systemic AAV delivery.

Moderna will get $50 million upfront and up to $110 million in near-term development and regulatory milestone payments, among other financial terms.

The trial will include patients with pancreatic, colorectal, non-small cell lung, and other cancers that harbor KRAS G12V mutations.

After a young woman develops mobility and speech issues, her grandmother seeks help from her genetic counselor, who flags a ...

At the World Economic Forum, CEO Stéphane Bancel expressed concern about the US vaccine market but remained committed to ...